Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy

The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Bonechi, Martina, Galardi, Francesca, Biagioni, Chiara, De Luca, Francesca, Bergqvist, Mattias, Neumüller, Magnus, Guarducci, Cristina, Boccalini, Giulia, Gabellini, Stefano, Migliaccio, Ilenia, Di Leo, Angelo, Pestrin, Marta, Malorni, Luca
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5893248/
https://ncbi.nlm.nih.gov/pubmed/29662653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24700
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares